Drug Profile
Research programme: platelet-derived growth factor receptor antagonists - Pulmokine
Alternative Names: PDGF receptor kinase inhibitors - PulmokineLatest Information Update: 28 Apr 2020
Price :
$50
*
At a glance
- Originator YM BioSciences
- Developer Pulmokine
- Class Antihypertensives; Small molecules
- Mechanism of Action Platelet-derived growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pulmonary arterial hypertension
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for preclinical development in Pulmonary-arterial-hypertension in USA (Inhalation)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pulmonary-arterial-hypertension in USA (Inhalation)
- 27 Mar 2014 Pulmokine receives Stage B Vascular Interventions and Therapeutic Advances (VITA) contract from National Heart, Lung and Blood Institute in the USA for inhaled PDGFR antagonists development in Pulmonary arterial hypertension